Confirmed Supporters


Confirmed Supporters

ISH 2018 would like to thank the following companies for their generous support:







Confirmed Exhibitors

Alexion is a global biopharmaceutical company focused on serving patients with devastating and rare diseases. Patients with these diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to develop and deliver therapies that will transform their lives. (
Amgen Canada
Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, cardiovascular disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients. (
Aplastic Anemia and Myelodysplasia Association of Canada
The Aplastic Anemia and Myelodysplasia Association of Canada (AAMAC) is a federally incorporated and registered national charity with the goal of providing a support network for every Canadian patient, caregiver and healthcare provider dealing with aplastic anemia, myelodysplasia or PNH. AAMAC is led by a volunteer board of directors and a distinguished team of medical advisors from across Canada. (
Canadian Hematology Society
The CHS, founded in 1971, represents Canadian hematologists. The organization’s main goals are to maintain the integrity and vitality of the hematology specialty in Canada, to encourage and reward scholarly research, and to provide a forum for communication and support for colleagues in the community and in academic settings. (
ISH 2020 Thailand
Attend the 38th World Congress of International Society of Hematology (ISH 2020) to hear the world-renowned experts present the latest updates in hematology researches and translate them into patient care improvements. This is a great opportunity to share experience, exchange knowledge and network with physicians and scientists around the world. September 13-17, 2020, Bangkok, Thailand. (
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We are Janssen. We collaborate with the world for the health of everyone in it. (
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the development of novel drugs targeting nuclear transport of tumor suppressor proteins and related mechanisms. To date, over 2,200 cancer patients have been treated with lead compound selinexor. Phase II or III studies are ongoing in multiple myeloma, DLBCL and liposarcoma. (
MDS Alliance
The MDS Alliance is an international umbrella organisation that aims to ensure MDS patients, regardless of where they live, have access to the best multi-professional care. We also aim to provide member organisations, patients and healthcare teams with the resources and the latest information about MDS, including current treatment options, large international projects and events of Interest to the whole community. (
Methapharm Specialty Pharmaceuticals
Methapharm is a privately held specialty pharmaceutical company with a focus on the acquisition, licensing and promotion of healthcare products in North America. Methapharm focuses on several therapeutic areas in Canada, but has a particular interest in Respiratory, Imaging, Hospital and Prescription Products. (
Taylor & Francis – Hematology
Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Hematology aims to bridge the interests and practices of both those carrying out laboratory work and those whose main inclination is towards patient care. The journal provides a forum where the clinical aspects of any published material will be emphasised. (
The MDS Foundation, Inc.
The MDS Foundation, Inc. (MDSF) is an international organization devoted to the support and education of patients and healthcare providers with innovative research in the fields of MDS and related myeloid neoplasms in order to accelerate progress leading to the control and cure of these diseases. (